Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparison of Glucagon Administered by Either the Nasal (LY900018) or Intra-muscular (GlucaGen) Routes in Adult Patients With Type 1 Diabetes Mellitus During Controlled Insulin-Induced Hypoglycemia

Next Previous
X
Search
Trial Profile

Comparison of Glucagon Administered by Either the Nasal (LY900018) or Intra-muscular (GlucaGen) Routes in Adult Patients With Type 1 Diabetes Mellitus During Controlled Insulin-Induced Hypoglycemia

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Glucagon (Primary) ; Glucagon
  • Indications Hypoglycaemia
  • Focus Therapeutic Use
  • Sponsors Eli Lilly and Company

    • Most Recent Events

    • 25 Sep 2020 Results pooled post hoc analyses of two randomised, cross-over studies (NCT03421379, NCT03339453) assessing efficacy, pharmacodynamics, and safety of nasal glucagon compared to injectable glucagon in reversing insulin induced hypoglycaemia in Caucasian and Japanese adults with type 1 diabetes or type 2 diabetes, presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
    • 25 Sep 2020 Results (n=214) of pooled post hoc analyses of 3 randomised, cross-over studies (NCT03421379, NCT03339453, NCT01994746) assessing efficacy and safety of nasal glucagon compared to 1 mg intramuscular injectable glucagon in reversing insulin-induced hypoglycaemia in adults with type 1 diabetes or type 2 diabetes, presented at the 56th Annual Meeting of the European Association for the Study of Diabetes.
    • 24 Jul 2019 Results presented in an Eli Lilly media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top